These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16164393)

  • 1. Infections associated with tumor necrosis factor-alpha antagonists.
    Rychly DJ; DiPiro JT
    Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
    Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis infections and tumor necrosis factor alpha antagonists.
    Gan J; Manadan AM; Sequiera W; Block JA
    Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
    Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
    Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
    Gómez-Reino JJ; Carmona L; Angel Descalzo M;
    Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
    Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
    Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
    Hernández MV; Meineri M; Sanmartí R
    Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of biologic therapies--an update.
    Keystone EC
    J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
    Keane J
    Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
    Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.
    Wood KL; Hage CA; Knox KS; Kleiman MB; Sannuti A; Day RB; Wheat LJ; Twigg HL
    Am J Respir Crit Care Med; 2003 May; 167(9):1279-82. PubMed ID: 12615627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.